Although there is no previous report describing the clinical application of cetuximab to oesophageal SCC patients, it has been shown that cetuximab-induced antitumour activity did not correlate directly with the levels of EGFR expression in human tumour xenograft models (Wild et al, 2006). The gene discussed is EGFR; the disease is neoplasm.